Melatonin as a selective estrogen enzyme modulator.

Area of Science:

• Endocrinology
• Oncology
• Molecular Biology

Background:

• Melatonin demonstrates oncostatic properties against various tumors, particularly hormone-dependent breast cancer.
• In vivo studies show melatonin reduces mammary tumor incidence and growth in rodents.
• In vitro research indicates melatonin inhibits human breast cancer cell proliferation and invasiveness.

Purpose of the Study:

• To investigate the mechanisms by which melatonin inhibits breast cancer growth.
• To explore melatonin's interaction with estrogen-signaling pathways in breast cancer.
• To evaluate melatonin's potential as a therapeutic agent for estrogen-dependent mammary tumors.

Main Methods:

• In vivo studies using chemically-induced mammary tumors in rodents.
• In vitro experiments with human breast cancer cells.
• Analysis of melatonin's effects on estrogen receptor activation and estrogen-metabolizing enzymes.

Main Results:

• Melatonin inhibits breast cancer cell proliferation and invasiveness.
• Melatonin modulates estrogen signaling through indirect neuroendocrine mechanisms, direct receptor interaction (SERM), and enzyme regulation (SEEM).
• Melatonin reduces aromatase, sulfatase, and 17beta-hydroxysteroid dehydrogenase activity while increasing estrogen sulfotransferase, thereby protecting mammary tissue.

Conclusions:

• Melatonin exhibits both SERM and SEEM properties, aligning with desired characteristics for breast cancer therapeutics.
• Melatonin's multifaceted action on estrogen biosynthesis and signaling pathways makes it a promising anticancer agent.
• Melatonin holds potential for the prevention and treatment of estrogen-dependent mammary tumors.